Search Results - "Fernandes, Daphne J"

  • Showing 1 - 5 results of 5
Refine Results
  1. 1

    Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes by Maximov, Philipp Y, McDaniel, Russell E, Fernandes, Daphne J, Korostyshevskiy, Valeriy R, Bhatta, Puspanjali, Mürdter, Thomas E, Flockhart, David A, Jordan, V Craig

    Published in British journal of pharmacology (01-12-2014)
    “…Background and Purpose Tamoxifen is a prodrug that is metabolically activated by 4‐hydroxylation to the potent primary metabolite 4‐hydroxytamoxifen (4OHT) or…”
    Get full text
    Journal Article
  2. 2

    Pharmacological Relevance of Endoxifen in a Laboratory Simulation of Breast Cancer in Postmenopausal Patients by MAXIMOV, Philipp Y, MCDANIEL, Russell E, FERNANDES, Daphne J, BHATTA, Puspanjali, KOROSTYSHEVSKIY, Valeriy R, CURPAN, Ramona F, JORDAN, V. Craig

    “…Tamoxifen is metabolically activated via a CYP2D6 enzyme system to the more potent hydroxylated derivatives 4-hydroxytamoxifen and endoxifen. This study…”
    Get full text
    Journal Article
  3. 3

    Influence of the Length and Positioning of the Antiestrogenic Side Chain of Endoxifen and 4‑Hydroxytamoxifen on Gene Activation and Growth of Estrogen Receptor Positive Cancer Cells by Maximov, Philipp Y, Fernandes, Daphne J, McDaniel, Russell E, Myers, Cynthia B, Curpan, Ramona F, Jordan, V. Craig

    Published in Journal of medicinal chemistry (12-06-2014)
    “…Tamoxifen has biologically active metabolites: 4-hydroxytamoxifen (4OHT) and endoxifen. The E-isomers are not stable in solution as Z-isomerization occurs. We…”
    Get full text
    Journal Article
  4. 4

    Abstract 4409: The characterization of isomerically stable fixed ring derivatives of tamoxifen metabolites 4-hydroxytamoxifen and 4-hydroxy-N-desmethyltamoxifen (endoxifen) in vitro by Maximov, Philipp Y., Myers, Cynthia, Fernandes, Daphne J., Jordan, V. Craig

    Published in Cancer research (Chicago, Ill.) (15-04-2013)
    “…Tamoxifen is the most widely used agent in the world for antihormonal therapy of Estrogen Receptor (ER)-positive breast cancer for both pre- and postmenopausal…”
    Get full text
    Journal Article
  5. 5